Studies have shown that XBP1 (or XBP1s) levels are positively correlated with bortezomib efficacy in patients with multiple myeloma [217], suggesting that XBP1s can act as a predictive marker of treatment outcomes. The gene discussed is XBP1; the disease is AL amyloidosis.